Literature DB >> 20036620

GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans.

Sang-Heon Kim1, Sang-Hoon Kim, Ho Joo Yoon, Dong Ho Shin, Sung Soo Park, Youn-Seup Kim, Jae-Seuk Park, Young Koo Jee.   

Abstract

Adverse reactions induced by antituberculosis drugs (ATD) often result in serious morbidities, impeding scheduled treatment and cure. In the development of ATD-induced adverse reactions, glutathione S-transferase has been suggested to play a protective role as an intracellular scavenger by conjugating toxic reactive metabolites of ATD. This study examined the association of null mutations in GST enzyme genes (GSTT1 and GSTM1) with the development of ATD-induced hepatitis and cutaneous reactions. We compared the frequencies of GSTT1 and GSTM1 null mutations in 57 patients with hepatitis, 94 patients with cutaneous adverse reactions, and 190 ATD-tolerant controls. The frequency of null mutations in GSTT1 and GSTM1 in patients with ATD-induced hepatitis was not significantly different from that of controls (59.6% vs. 54.2% and 45.6% vs. 54.7%, respectively). Additionally, no significant difference was observed in the frequency of either null mutation in patients with ATD-induced cutaneous reactions, including maculopapular eruption, compared with controls (58.5% vs. 54.1% for GSTT1 and 59.6% vs. 54.6% for GSTM1). These findings indicate that GSTT1 and GSTM1 null mutations are not associated with the development of ATD-induced hepatitis or cutaneous reactions in this Korean population, and suggest that glutathione S-transferase enzymes do not play important roles in the pathogenesis of these conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036620     DOI: 10.1016/j.tube.2009.12.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  13 in total

1.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

2.  NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.

Authors:  Sang-Heon Kim; Sang-Hoon Kim; Ho Joo Yoon; Dong Ho Shin; Sung Soo Park; Youn-Seup Kim; Jae-Seuk Park; Young Koo Jee
Journal:  Eur J Clin Pharmacol       Date:  2010-10-13       Impact factor: 2.953

Review 3.  GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.

Authors:  C Li; J Long; X Hu; Y Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-02       Impact factor: 3.267

4.  Meta-Analysis-Based Preliminary Exploration of the Connection between ATDILI and Schizophrenia by GSTM1/T1 Gene Polymorphisms.

Authors:  Lei Cai; Mei-Hong Cai; Mei-Yan Wang; Yi-Feng Xu; Wen-Zhong Chen; Shen-Ying Qin; Chun-Ling Wan; Lin He
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

5.  Superoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis.

Authors:  Sang-Hoon Kim; Sang-Heon Kim; Jae-Hyoung Lee; Byoung-Hoon Lee; Ho Joo Yoon; Dong Ho Shin; Sung Soo Park; Suk Bin Jang; Jae-Seuk Park; Young-Koo Jee
Journal:  Allergy Asthma Immunol Res       Date:  2014-09-25       Impact factor: 5.764

6.  Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients.

Authors:  Fang Liu; An-xia Jiao; Xi-rong Wu; Wei Zhao; Qing-qin Yin; Hui Qi; Wei-wei Jiao; Jing Xiao; Lin Sun; Chen Shen; Jian-ling Tian; Dan Shen; Evelyne Jacqz-Aigrain; A-dong Shen
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

7.  ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.

Authors:  Sang-Heon Kim; Young-Koo Jee; Jae-Hyung Lee; Byoung-Hoon Lee; Youn-Seup Kim; Jae-Seuk Park; Sang-Hoon Kim
Journal:  Allergy Asthma Immunol Res       Date:  2012-05-24       Impact factor: 5.764

8.  Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.

Authors:  Yu Cai; JiaYong Yi; ChaoHui Zhou; XiZhong Shen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

9.  The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Authors:  Yang Xiang; Long Ma; Weidong Wu; Wei Liu; Yongguang Li; Xia Zhu; Qian Wang; Jinfeng Ma; Mingqin Cao; Qian Wang; Xuemei Yao; Lei Yang; Atikaimu Wubuli; Corinne Merle; Paul Milligan; Ying Mao; Jiayi Gu; Xiumei Xin
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.

Authors:  Eun Kyoung Chung; Jangik I Lee; Seungwon Yang; Se Jung Hwang; Jung Yun Park
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.